Figure 7.

Depiction of representative nanotechnology‐based strategies to optimize CAR‐T cell therapy: A) polymeric NPs to optimize gene delivery and the in situ generation of CARs; B) surface‐conjugated nanogels to improve T cell expansion; C) liposome‐encapsulated proteins leading to T cell activation; D) NPs preconditioning tumor to promote T cell penetration and antitumor activity; E) NPs coupled with checkpoint inhibitors to induce CAR‐T cell trafficking; F) synthetic antigen receptor to overcome immunosuppressive tumor‐associated cells and vessels by different mechanisms; G) radio‐labeled NPs for CAR‐T cell tracking.